Japan Limits Company Contributions To Drug Review Board Members
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare approved a new rule regulating the voting rights of review board members. The rule states that members of the drug review board who received more than ¥5 million in a single year over the past three years will not be allowed to review and vote on applications, and members who received more than ¥500,000 but less than ¥5 million will not be able to vote.The scope of contributions include: contributions to scholarships, compensation such as patient usage fees and contributions to voting members' immediate relatives.Last year, Chugai Pharmaceutical, the Japanese distributor of Tamiflu (oseltamivir), was found contributing money to members of a research team studying the relationship between abnormal behavior and Tamiflu use. The new regulation is an effort to keep MHLW's drug approval procedure fair and transparent. (Click here for more
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.